口服骨化三醇对接受RAS阻断剂的IgA肾病患者的附加肾脏保护作用
这项双盲安慰剂对照试验纳入138例活检确诊、已最大剂量使用RAS阻断剂后仍有持续蛋白尿(0.5-3.5 g/天)的IgA肾病患者,随机接受0.25 μg/天骨化三醇或安慰剂治疗12个月。骨化三醇组UPCR和尿白蛋白肌酐比的下降幅度均显著大于安慰剂组,且eGFR年下降斜率更小,不良事件与安慰剂相当。
要点
- 骨化三醇0.25 μg/天可显著降低IgA肾病患者残余蛋白尿。
- 骨化三醇组eGFR年下降幅度小于安慰剂组,提示延缓肾功能下降。
- 不良事件与安慰剂相当,安全性可接受。
核心结论
- 在已最大剂量使用RAS阻断剂的IgA肾病患者中,加用0.25 μg/天骨化三醇可安全降低残余蛋白尿并减缓eGFR下降。
- 提示骨化三醇在该人群中有潜在治疗作用。
研究设计与样本
- 双盲、安慰剂对照试验,纳入活检确诊的IgA肾病患者。
- 入组条件为最大剂量使用RAS阻断剂后仍有持续蛋白尿0.5-3.5 g/天。
- 共138例来自六家医疗中心,随机分配至安慰剂组(n=69)或骨化三醇0.25 μg/天组(n=69),治疗12个月。
- 115例(83.3%)完成研究。
- 主要结局为治疗期间平均尿蛋白肌酐比(UPCR)和每日尿蛋白排泄量的变化。
主要发现
- 不良事件两组相当。
临床怎么用
- 对已最大剂量使用RAS阻断剂但仍有残余蛋白尿的IgA肾病患者,可考虑加用0.25 μg/天骨化三醇以进一步降低蛋白尿并延缓eGFR下降。
- 用药期间需监测不良事件,本研究显示与安慰剂相当。
局限性
- 研究仅纳入蛋白尿0.5-3.5 g/天的患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with immunoglobulin A nephropathy (IgAN) and moderate proteinuria are at risk of progressive renal failure despite the maximal use of renin-angiotensin system blockers (RASBs). This study evaluated the efficacy of active vitamin D in reducing proteinuria in patients with IgAN receiving RASBs. METHODS: In this double-blind, placebo-controlled trial, we enrolled biopsy-confirmed patients with IgAN and persistent proteinuria (0.5-3.5 g/day) after maximal use of RASBs. Patients were randomized to receive either 0.25 μg/day of calcitriol or placebo for 12 months. The primary outcomes were the change in the mean urinary protein:creatinine ratio (UPCR) and daily urinary protein excretion during the treatment. RESULTS: A total of 138 patients from six medical centres were enrolled and assigned to receive a placebo (n = 69) or 0.25 μg of calcitriol (n = 69) and 115 patients (83.3%) completed the study. The calcitriol group showed a greater reduction in geometric means of UPCR {mean difference -187 mg/g [95% confidence interval (CI) -370.6 to -4.0], P = .04} and urinary albumin:creatinine ratio [-162 mg/g (95% CI -290.9 to -34.6), P = .01] than placebo. Changes in daily urinary protein excretion were -3.5% (from 1.32 to 1.02 g/day) in the control group and -13.1% (from 1.29 to 0.97 g/day) in the calcitriol group, without any statistically significant differences (P = .11). The annual decrease of the estimated glomerular filtration rate (eGFR) was -0.32 ml/min/1.73 m2 (95% CI -2.54 to 1.99) in the calcitriol group and -3.64 ml/min/1.73 m2 (95% CI -5.70 to -1.58) in the placebo group (calcitriol versus placebo over time, P = .02). Adverse events were comparable between the groups. CONCLUSION: The addition of 0.25 μg/day calcitriol to RASBs safely lowered residual proteinuria and slowed the eGFR decline in patients with IgAN, suggesting a potential therapeutic role for calcitriol in this population.
引用
- Joo YS, Chang TI, Kim DK, et al. Additive renoprotective effects of oral calcitriol on patients with IgA nephropathy receiving RAS blockers. Nephrol Dial Transplant. 2026. PMID: 41178795. doi:10.1093/ndt/gfaf187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。